Goals: to improve health outcomes of those with fungal infections or allergies by delivering free educational resources and the latest news to health professionals around the world.
- Increased awareness of when to suspect a fungal infection in different clinical settings and scenarios
- Rapid and accurate diagnosis, including selecting the right laboratory tests
- Selection of the best evidence-based treatment, based on antifungals
Style: clinicians’ time is precious, so we summarise the take-home messages that help you to improve/sharpen your clinical practice. We provide the full text if you want to read the full thing.
Target audience: doctors, nurses, radiologists, laboratory staff, ophthalmologists, critical care units, paediatricians, transplant centres, physiotherapists, epidemiologists, public health professionals, general practitioners, dermatologists, HIV/AIDS centres.
International outlook: each country faces a different set of challenges depending on endemic mycoses and prevalence of underlying factors (e.g. HIV/AIDS, TB). Each healthcare system is different, and may be limited by factors such as funding and which drugs are registered in that country. However, high-quality education in multiple languages can help everyone to make the best of what resources are available.
Location and funding: we are based within the National Aspergillosis Centre at Wythenshawe Hospital (part of Manchester University NHS Foundation Trust). We are supported by the Fungal Infection Trust, a UK charitable foundation set up 20 years ago.
Professor David Denning has been caring for patients with fungal infections for 30 years.
- Founded the National Aspergillosis Centre (Manchester, UK), a specialist NHS care commissioning group that treats x00 patients with , ABPA and other forms of aspergillosis and provides information and support to patients and their doctors.
- Founded the spinout company F2G Ltd, which is currently conducting a phase 2b clinical trial of olorofim (formerly F901318), an orotomide antifungal with a novel mechanism of action.
- Founded Myconostica Ltd, which develops rapid molecular diagnostics for invasive fungal infections.
- Scientific Director of the Fungal Infection Trust, as UK charitable foundation (Charity Commission no. 1147658).
- President of the Global Action For Fungal Infections ( ), an advocacy organisation that pushes for universal access to fungal diagnostics and treatments, for example by ensuring they are represented on the WHO Essential Diagnostics List and Essential Medicines List.
- Active participant in drafting guidelines and the mycoses section of the ICD-11.
- Read his publications
Beth Bradshaw (Medical Writer & Web Manager) joined the LIFE team in 2017.
- Writes content for and helps to manage several other websites and groups based at the National Aspergillosis Centre, including Aspergillus&Aspergillosis, , MRCM laboratory,
- Helps to run Aspergillosis patient support groups groups (Facebook public and private groups, patients and carers website, Zoom meetings).
- Trained in molecular microbiology at the John Innes Centre (PhD) and Technical University of Delft (postdoc) before training as a medical writer at Ashfield Healthcare Communications.
- Previously worked as Publications Manager for the NHS West Midlands Genetic Regional Laboratory (Birmingham), and as part of the clinical trials team at Stepping Hill Hospital (Stockport).
- Read her publications